Search

Your search keyword '"Trippa, F"' showing total 133 results
Start Over Author "Trippa, F" Language english
133 results on '"Trippa, F"'

5. 19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study)

Author

Macchia, G, Lazzari, R, Colombo, N, Laliscia, C, Capelli, G, D’Agostino, GR, Deodato, F, Trippa, F, Ippolito, E, Ronchi, S, Pajar, F, Scorsetti, M, Cilla, S, Ingargiola, R, Huscher, A, Cerrotta, AM, Andrei, F, Vicenzi, L, Russo, D, Borghesi, S, Perrucci, E, Pignata, S, Aristei, C, Morganti, AG, Scambia, G, Valentini, V, Jereczek-Fossa, BA, and Ferrandina, G

Published
2019
Full Text
View/download PDF

10. 126P Chemotherapy and stereotactic ablative radiotherapy in newly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrent radiochemotherapy: Sub-analysis and update of START-NEW-ERA non-randomised phase II trial

Author

Arcidiacono, F., Anselmo, P., Casale, M., Zannori, C., Loreti, F., Italiani, M., Enrico, B., Fabiani, S., Marchetti, G., Tassi, V., Mancioli, F.A., Muti, M., Guida, A., Bracarda, S., Ragusa, M., Maranzano, E., and Trippa, F.

Published
2023
Full Text
View/download PDF

11. Salvage Radiotherapy Guided by Functional Imaging for Macroscopic Local Recurrence Following Radical Prostatectomy: A Multicentric Retrospective Study

Author

Benziane-Ouaritini, N., Zilli, T., Ingrosso, G., di Staso, M., Trippa, F., Francolini, G., Meyer, E., Achard, V.M., Schick, U., Cosset, J.M., Martin, E., Penna, R. Renard, Ferrari, V., Giraud, N., Pasquier, C., Magne, N., Anger, E., Aristei, C., Perrenec, T., Gnep, K., Pasquier, D., Supiot, S., Sargos, P., and Latorzeff, I.

Published
2022
Full Text
View/download PDF

12. SC189 - Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Cannoletta, C., Fossati, N., Karnes, R., Heidenreich, A., Stief, C., Battaglia, A., Joniau, S., Osmonov, D., Shariat, S., Albers, P., Tilki, D., Gill, I., Mottrie, A., Jereczek-Fossa, B., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., De Iturriaga, A., Trippa, F., Detti, B., and Ost, P.

Published
2019
Full Text
View/download PDF

19. 772 - Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Fossati, N., Karnes, R.J., Heidenreich, A., Stief, C., Battaglia, A., Joniau, S., Osmonov, D., Shariat, S., Albers, P., Tilki, D., Gill, I.S., Mottrie, A., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., De Iturriaga, A.G., Trippa, F., Detti, B., and Ost, P.

Published
2019
Full Text
View/download PDF

20. 771 - Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

Author

De Bleser, E., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez De Iturriaga, A., Trippa, F., Detti, B., Ingrosso, G., Triggiani, L., Alessio, B., Alongi, F., Reynders, D., Fonteyne, V., Surgo, A., Loukili, K., Miralbell, R., Silva, P., Chander, S., Goetghebeur, E., and Ost, P.

Published
2019
Full Text
View/download PDF

21. 'Hypofractionated radiotherapy in'

Author

Lupatelli, M, Amelio, D, Anselmo, P, Scoccianti, S, Beneventi, S, Bellavita, R, Bagnoli, R, Trippa, F, Mirri, Ma, Magrini, Stefano Maria, Checcaglini, F, and Aristei, C.

Published
2008

27. Radiation-induced emesis: A prospective observational multicenter Italian trial

Author

Maranzano, E, Latini, P, Roila, F, De Angelis, V, Tonato, M, Ballatori, E, Del Favero, A, Ciccarese, G, Palladino, Ma, Galardi, A, Cintolesi, V, Sulprizio, S, Biti, G, Dessi, M, Maxia, G, Lupattelli, M, Piro, F, Bellavita, R, Bianchi, P, Timurian, D, Dal Fior, S, Iannone, T, Bonanno, I, Magno, L, Fillini, C, Marchetti, G, Giudici, S, Corvo, R, Mignogna, M, Sargenti, A, DE RENZIS, Costantino, Sansotta, G, Di Russo, A, Ricci, Sb, Sciume, F, Liotta, P, Del Duca, M, Emiliani, E, Morganti, Ag, Cellini, N, Mandoliti, G, Polico, C, Trippa, F, Checcaglini, F, Sola, B, Trotti, Ab, Ponticelli, P, Lombardi, R, Sarti, E, Moro, G, Iacopino, B, Galuppi, A, Palmucci, T, La Monica MM, Leggio, M, Lonardi, F, Marzi, M, Di Marco, A, Pergolizzi, Stefano, Pizzi, G, Cerrotta, A, Orecchia, R, Barsacchi, L, Silvestro, G, Scoppa, G, Franchini, P, Vanzo, C, Cristallini, S, D'Abbiero, N, Salvi, G, Tombolini, V, Parisi, S, Alfieri, M, Sebaste, L, Malinverni, G., Tomio, L, Buffoli, A, and Pradella, R.

Published
1999

35. PO-1021: Stereotactic radiotherapy for unresectable locally advanced non small cell lung cancer.

Author

Arcidiacono, F., Anselmo, P., Trippa, F., Casale, M., Italiani, M., Draghini, L., Terenzi, S., Fabiani, S., Di Marzo, A., and Maranzano, E.

Subjects
*STEREOTACTIC radiotherapy
Abstract

Poster: Clinical track: Lung PO-1021: Stereotactic radiotherapy for unresectable locally advanced non small cell lung cancer F. Arcidiacono, P. Anselmo, F. Trippa, M. Casale, M. Italiani, L. Draghini, S. Terenzi, S. Fabiani, A. Di Marzo, E. Maranzano. [Extracted from the article]

Published
2020
Full Text
View/download PDF

38. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy

Author

Luca Marinelli, Giulio Francolini, Stefano Maria Magrini, Daniela Musio, Maurizio Valeriani, Alessio Bruni, Beatrice Detti, Ernesto Maranzano, Saverio Caini, Cynthia Aristei, N. Di Muzio, Andrei Fodor, Andrea Lancia, Simona Borghesi, Gianluca Ingrosso, D. Russo, Fabio Trippa, Lorenzo Livi, Luca Triggiani, Ingrosso, G., Detti, B., Fodor, A., Caini, S., Borghesi, S., Triggiani, L., Trippa, F., Russo, D., Bruni, A., Francolini, G., Lancia, A., Marinelli, L., Di Muzio, N., Livi, L., Magrini, S. M., Maranzano, E., Musio, D., Aristei, C., and Valeriani, M.

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Oligoprogression, medicine.drug_class, Stereotactic body radiotherapy, medicine.medical_treatment, Kaplan-Meier Estimate, Radiosurgery, Targeted therapy, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Internal medicine, Androgen Receptor Antagonists, medicine, Humans, Molecular Targeted Therapy, Survival analysis, Androgen receptor-targeted therapy, Aged, Retrospective Studies, Analysis of Variance, business.industry, Metastatic castration-resistant prostate cancer, NEST-free survival, Hazard ratio, Radiotherapy Dosage, Common Terminology Criteria for Adverse Events, General Medicine, Middle Aged, Androgen, medicine.disease, Combined Modality Therapy, Progression-Free Survival, Radiation therapy, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Toxicity, Disease Progression, business
Abstract

Objectives: To report outcomes of stereotactic body radiotherapy (SBRT) in metastatic castration-resistant prostate cancer (mCRPC) patients with oligoprogression (≤ 5 metastases) during first-line treatment with androgen receptor-targeted therapy (ARTT). Patients and methods: Retrospective multi-institutional analysis of mCRPC patients treated with SBRT to oligoprogressive lesions during ARTT. End-points were time to next-line systemic treatment (NEST), radiological progression-free survival (r-PFS) and overall survival (OS). Toxicity was registered according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Survival analysis was performed using the Kaplan–Meier method, univariate and multivariate analysis (MVA) were performed. Results: Data from 34 patients were analyzed. Median NEST-free survival, r-PFS, and OS were 16.97, 13.47, and 38.3months, respectively. At MVA, factors associated with worse NEST-free survival and r-PFS were polymetastatic burden at diagnosis of metastatic hormone-sensitive disease (hazard ratio [HR] 3.66, p = 0.009; HR 3.03, p = 0.034), PSA ≤ 7ng/ml at mCRPC diagnosis (HR 0.23, p = 0.017; HR 0.19, p = 0.006) and PSADT ≤ 3months at mCRPC diagnosis (HR 3.39, p = 0.026; HR 2.79, p = 0.037). Polymetastatic state at mHSPC diagnosis was associated with a decreased OS (HR 4.68, p = 0.029). No patient developed acute or late grade ≥ 2 toxicity. Conclusion: Our results suggest that SBRT in oligoprogressive mCPRC is safe, effective and seems to prolong the efficacy of the ongoing systemic treatment positively affecting disease progression. Prospective trials are needed.

Published
2021

42. PH-0356: Long-term results after radiosurgery (SRS) of vestibular schwannomas (VS). A retrospective analysis.

Author

Anselmo, P., Pinzi, V., Terenzi, S., De Martin, E., Trippa, F., Gaviani, P., Casale, M., Fariselli, L., and Maranzano, E.

Subjects
*SCHWANNOMAS, *RADIOSURGERY, *RETROSPECTIVE studies
Abstract

PH-0356: Long-term results after radiosurgery (SRS) of vestibular schwannomas (VS). P. Anselmo, V. Pinzi, S. Terenzi, E. De Martin, F. Trippa, P. Gaviani, M. Casale, L. Fariselli, E. Maranzano, Poster Highlights: Poster highlights 11 CL: CNS PH-0356: Long-term results after radiosurgery (SRS) of vestibular schwannomas (VS). [Extracted from the article]

Published
2020
Full Text
View/download PDF

43. PH-0118: Stereotactic or conventional RT for macroscopic prostate bed recurrence: a propensity score analysis.

Author

Francolini, G., Jereczek-Fossa, B.A., Di Cataldo, V., Simontacchi, G., Marvaso, G., Zerella, M.A., Gentile, P., Bianciardi, F., Allegretta, S., Detti, B., Masi, L., Ciccone, L.P., Bruni, A., Ingrosso, G., Mazzeo, E., Trippa, F., Lohr, F., and Livi, L.

Subjects
*PROSTATE, *POSTERS
Abstract

Poster Highlights: Poster highlights 3 CL: Prostate PH-0118: Stereotactic or conventional RT for macroscopic prostate bed recurrence: a propensity score analysis G. Francolini, B.A. Jereczek-Fossa, V. Di Cataldo, G. Simontacchi, G. Marvaso, M.A. Zerella, P. Gentile, F. Bianciardi, S. Allegretta, B. Detti, L. Masi, L.P. Ciccone, A. Bruni, G. Ingrosso, E. Mazzeo, F. Trippa, F. Lohr, L. Livi. [Extracted from the article]

Published
2020
Full Text
View/download PDF

44. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy

Author

Giulia Marvaso, Raymond Miralbell, Alfonso Gomez-Iturriaga, Elise De Bleser, Nicholas van As, Chiara Lucrezia Deantoni, Shankar Siva, Giulio Francolini, Beatrice Detti, Els Goetghebeur, Fabio Trippa, Piet Ost, Sarat Chander, Pedro Silva, Alison Tree, Ernesto Maranzano, Alessia Surgo, Filippo Alongi, Gert De Meerleer, Kaoutar Loukili, Luca Triggiani, Dries Reynders, Thomas Zilli, Nadia Di Muzio, Andrea Lancia, Piet Dirix, Barbara Alicja Jereczek-Fossa, Alessio Bruni, Andrei Fodor, David Pasquier, Gianluca Ingrosso, Elisabetta Ponti, De Bleser, E., Jereczek-Fossa, B. A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez-Iturriaga, A., Trippa, F., Detti, B., Ingrosso, G., Triggiani, L., Bruni, A., Alongi, F., Reynders, D., De Meerleer, G., Surgo, A., Loukili, K., Miralbell, R., Silva, P., Chander, S., Di Muzio, N. G., Maranzano, E., Francolini, G., Lancia, A., Tree, A., Deantoni, C. L., Ponti, E., Marvaso, G., Goetghebeur, E., and Ost, P.

Subjects
Male, medicine.medical_specialty, Elective nodal radiotherapy, Metastasis-directed therapy, Oligometastasis, Oligorecurrence, Prostatic neoplasms, Radiotherapy, Recurrence, Stereotactic ablative body radiotherapy, Stereotactic body radiotherapy, Urology, medicine.medical_treatment, 030232 urology & nephrology, Radiosurgery, ddc:616.0757, Metastasis, Androgen deprivation therapy, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Interquartile range, Clinical endpoint, Medicine, Humans, Aged, Retrospective Studies, business.industry, Prostatectomy, Prostatic Neoplasms, Middle Aged, medicine.disease, Radiation therapy, Treatment Outcome, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Radiology, Human medicine, Neoplasm Recurrence, Local, business
Abstract

Background: Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT) are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer (PC); however, comparative data are still lacking. Objective: To compare outcome and toxicity between both treatments. Primary endpoint was metastasis-free survival, adjusted for selected variables (aMFS). Design, setting, and participants: This was a multi-institutional, retrospective analysis of 506 (SBRT: 309, ENRT: 197) patients with hormone-sensitive nodal oligorecurrent PC (five or fewer lymph nodes (LNs; N1/M1a), treated between 2004 and 2017. Median follow-up was 36 mo (interquartile range 23-56). Intervention: SBRT was defined as a minimum of 5 Gy per fraction to each lesion with a maximum of 10 fractions. ENRT was defined as a minimum dose of 45 Gy in up to 25 fractions to the elective nodes, with or without a simultaneous boost to the suspicious node(s). The choice of radiotherapy (RT) was at the discretion of the treating physician, with treatments being unbalanced over the centers. Outcome measurements and statistical analysis: In total, 506 patients from 15 different treatment centers were included. Primary treatment was radical prostatectomy, RT, or their combination. Nodal recurrences were detected by positron emission tomography/computer tomography (97%) or conventional imaging (3%). Descriptive statistics was used to summarize patient characteristics. Results and limitations: ENRT was associated with fewer nodal recurrences compared with SBRT (p

Published
2019

45. P046 - Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis.

Author

De Bleser, E., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez De Iturriaga, A., Trippa, F., Detti, B., Ingrosso, G., Triggiani, L., Alessio, B., Alongi, F., Fonteyne, V., Surgo, A., Loukili, K., Miralbell, R., and Pedro, S.

Subjects
*CANCER radiotherapy, *PROSTATE cancer, *RADIOISOTOPE brachytherapy, *STEREOTACTIC radiotherapy, *CANCER treatment
Published
2018
Full Text
View/download PDF

49. Can interventional radiotherapy (brachytherapy) be an alternative to surgery in early-stage oral cavity cancer? A systematic review.

Author

Draghini L, Lancellotta V, Fionda B, De Angeli M, Cornacchione P, Massaccesi M, Trippa F, Kovács G, Morganti AG, Bussu F, Iezzi R, and Tagliaferri L

Subjects
Humans, Neoplasm Staging, Disease-Free Survival, Treatment Outcome, Brachytherapy methods, Mouth Neoplasms radiotherapy
Abstract

Purpose: Brachytherapy (BT), also known as interventional radiotherapy (IRT), has proven its utility in the treatment of localized tumors. The aim of this review was to examine the efficacy of modern BT in early-stage oral cavity cancer (OCC) in terms of local control (LC), overall survival (OS), disease-free survival (DFS), cancer-specific survival (CSS), and safety., Methods: The SPIDER framework was used, with sample (S), phenomena of interest (PI), design (D), evaluation (E), and research type (R) corresponding to early-stage oral cavity cancer (S); BT (PI); named types of qualitative data collection and analysis (D); LC, OS, DFS, CSS, and toxicity (E); qualitative method (R). Systematic research using PubMed and Scopus was performed to identify full articles evaluating the efficacy of BT in patients with early-stage OCC. The studies were identified using medical subject headings (MeSH). We also performed a PubMed search with the keywords "brachytherapy oral cavity cancer, surgery." The search was restricted to the English language. The timeframe 2002-2022 as year of publication was considered. We analyzed clinical studies of patients with OCC treated with BT alone only as full text; conference papers, surveys, letters, editorials, book chapters, and reviews were excluded., Results: The literature search resulted in 517 articles. After the selection process, 7 studies fulfilled the inclusion criteria and were included in this review, totaling 456 patients with early-stage node-negative OCC who were treated with BT alone (304 patients). Five-year LC, DFS, and OS for the BT group were 60-100%, 82-91%, and 50-84%, respectively., Conclusion: In conclusion, our review suggests that BT is effective in the treatment of early-stage OCC, particularly for T1N0 of the lip, mobile tongue, and buccal mucosa cancers, with good functional and toxicity profiles., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)

Published
2024
Full Text
View/download PDF

50. Image-guided moderately hypofractionated radiotherapy for localized prostate cancer: a multicentric retrospective study (IPOPROMISE).

Author

Ingrosso G, Ponti E, Francolini G, Caini S, Fondelli S, Santini R, Valeriani M, Rago L, Duroni G, Bruni A, Augurio A, Tramacere F, Trippa F, Russo D, Bottero M, Tamburo M, Parisi S, Borghesi S, Lancia A, Gomellini S, Scoccianti S, Stefanacci M, Vullo G, Statuto T, Miranda G, Santo B, Di Marzo A, Bellavita R, Vinciguerra A, Livi L, Aristei C, Bertini N, Orsatti C, and Detti B

Subjects
Male, Humans, Retrospective Studies, Androgen Antagonists, Prospective Studies, Neoplasm Recurrence, Local, Prostatic Neoplasms radiotherapy, Radiotherapy, Image-Guided methods, Radiotherapy, Intensity-Modulated methods
Abstract

Background: Moderate hypofractionated radiotherapy is a treatment option for the cure of localized prostate cancer (PCa) patients based on the results of randomized prospective trials, but there is a clinical concern about the relatively short length of follow-up, and real-world results on outcome and toxicity based on cutting-edge techniques are lacking. The objective of this study is to present the long-term results of a large multicentric series., Materials and Methods: We retrospectively evaluated 1325 PCa patients treated with daily volumetric image-guided hypofractionated radiotherapy between 2007 and 2020 in 16 Centers. For survival endpoints, we used Kaplan-Meier survival curves and fitted univariate and multivariable Cox's proportional hazards regression models to study the association between the clinical variables and each survival type., Results: At the end of the follow-up, 11 patients died from PCa. The 15-year values of cancer-specific survival (CSS) and biochemical relapse-free survival (b-RFS) were 98.5% (95%CI 97.3-99.6%) and 85.5% (95%CI 81.9-89.4%), respectively. The multivariate analysis showed that baseline PSA, Gleason score, and the use of androgen deprivation therapy were significant variables for all the outcomes. Acute gastrointestinal (GI) and genitourinary (GU) toxicities of grade ≥ 2 were 7.0% and 16.98%, respectively. The 15-year late grade ≥ 2 GI and GU toxicities were 5% (95%CI 4-6%) and 6% (95%CI 4-8%), respectively., Conclusion: Real-world long-term results of this multicentric study on cutting-edge techniques for the cure of localized PCa demonstrated an excellent biochemical-free survival rate of 85.5% at 15 years, and very low rates of ≥ G3 late GU and GI toxicity (1.6% and 0.9% respectively), strengthening the results of the available published trials., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results